Administration of dual antiplatelet therapy (DAPT) comprising of aspirin plus ticagrelor, for one year after coronary artery bypass grafting (CABG) results in less narrowing of the vein used to bypass a blocked artery , as compared to when aspirin is administered alone. It implies that Aspirin & ticagrelor combo improves outcomes after elective CABG. This is conclusion of a study done by Qiang Zhao, researcher at Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China, and colleagues, which was published in the Journal of the American Medical Association.
This study holds importance as according to previous data, the rate of failure of a graft of a saphenous vein was approximately 15% to 20% within one year after coronary artery bypass grafting (CABG) surgery and was associated with worse long-term outcomes. Antiplatelet therapy with aspirin improves vein graft patency .
Though the trial has some limitations as it was designed specifically for examination of saphenous vein graft patency so the results cannot be generalized to include arterial grafts. And also, the trial was not equipped to identify a significant effect on the incidence of major adverse cardiac events or other secondary and bleeding outcomes.
For carrying out the research, 500 patients who underwent CABG were enrolled in a randomized clinical trial in 2014 and 2015, with final follow-up in early 2017. Within 24 hours after CABG, 168 patients received ticagrelor (twice daily) and aspirin (once daily); 166 patients received ticagrelor (twice daily); 166 patients received aspirin (once daily) (interventions); patency of the grafted vein (less than 50% narrowing) one year after CABG (outcome).
.The Researchers concluded tat among patients undergoing elective CABG with saphenous vein grafting, ticagrelor + aspirin significantly increased graft patency after 1 year vs aspirin alone; there was no significant difference between ticagrelor alone and aspirin alone.However further research with more patients is needed to assess comparative bleeding risks.
Medha Baranwal joined Medical Dialogues as a Desk Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University.
She can be contacted at firstname.lastname@example.org.
Contact no. 011-43720751
Dear user, we've recently made some changes in our website to make it more secure & accessible. We request you to Reset your password in case you get any problem in logging in your account. For any help, contact : Support
Please activate your account
Please click on the "account activation link" we have sent to your registered email.